Related Experiment Video
Updated: Jul 19, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Adjuvant therapy for renal cell carcinoma.
Kenneth M Jacobsohn1, Christopher G Wood
1The University of Texas Health Science Center-Houston, Houston, TX, USA.
Seminars in Oncology
|October 19, 2006
Summary
No effective adjuvant therapy currently exists for high-risk kidney cancer (renal cell carcinoma) patients post-surgery. Future trials will investigate newer targeted agents to prevent metastatic disease relapse.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Renal cell carcinoma (RCC) is a common kidney tumor, with a significant percentage diagnosed with metastatic disease or developing it post-surgery.
- Currently, no proven adjuvant therapy is available for high-risk RCC patients to prevent relapse after surgical treatment.
- Past adjuvant treatment strategies like radiotherapy, chemotherapy, immunotherapy, and hormonal therapy have been unsuccessful.
Purpose of the Study:
- To review the historical, current, and future landscape of adjuvant therapy for renal cell carcinoma.
- To highlight the unmet need for effective treatments in high-risk RCC patients post-nephrectomy.
Main Methods:
- Literature review of past, present, and emerging adjuvant therapies for renal cell carcinoma.
- Discussion of molecular understanding driving targeted therapeutic approaches.
Main Results:
- Previous adjuvant therapies have largely failed to demonstrate efficacy in preventing RCC relapse.
- Newer targeted agents are under investigation for their potential in the adjuvant setting.
Conclusions:
- There is a critical need for effective adjuvant therapies to improve outcomes for high-risk renal cell carcinoma patients.
- Ongoing research into novel agents like thalidomide, vitespin, WX-G250, sorafenib, and sunitinib offers future hope for preventing metastatic disease.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...